This brand name is authorized in United States. It is also authorized in Australia, Brazil, Canada, Croatia, Ecuador, Estonia, Finland, Hong Kong SAR China, Ireland, Israel, Japan, Malta, Mexico, Netherlands, New Zealand, Poland, Singapore, South Africa, UK.
The drug PROVERA contains one active pharmaceutical ingredient (API):
1
|
UNII
C2QI4IOI2G - MEDROXYPROGESTERONE ACETATE
|
|
Medroxyprogesterone acetate exerts anti-oestrogenic, anti-androgenic and antigonadotrophic effects. |
|
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| PROVERA Tablet | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| G03AC06 | Medroxyprogesterone | G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03A Hormonal contraceptives for systemic use → G03AC Progestogens |
| G03DA02 | Medroxyprogesterone | G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03D Progestogens → G03DA Pregnen (4) derivatives |
| L02AB02 | Medroxyprogesterone | L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02A Hormones and related agents → L02AB Progestogens |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| AU | Pharmaceutical Benefits Scheme | 2316X, 2321E, 2323G, 2722G, 2725K, 2727M, 2728N |
| BR | Câmara de Regulação do Mercado de Medicamentos | 522717120067907 |
| CA | Health Products and Food Branch | 00030937, 00708917, 00729973 |
| EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | 28850-05-09, 28854-05-09 |
| EE | Ravimiamet | 1009022, 1009044, 1063594, 1083541, 1764019 |
| FI | Lääkealan turvallisuus- ja kehittämiskeskus | 500066 |
| GB | Medicines & Healthcare Products Regulatory Agency | 143567, 143574, 162293, 176262, 21979, 21984, 22017, 22019, 22022, 22134, 22135, 28266, 28289, 374122, 374129, 374130, 381931, 38689 |
| HK | Department of Health Drug Office | 00445, 00488 |
| HR | Agencija za lijekove i medicinske proizvode | HR-H-573087443, HR-H-701292304 |
| IE | Health Products Regulatory Authority | 43628, 43637, 43645 |
| IL | מִשְׂרַד הַבְּרִיאוּת | 128 |
| JP | 医薬品医療機器総合機構 | 2478002F1070 |
| MT | Medicines Authority | AA565/00102, AA565/00103, AA565/00104 |
| MX | Comisión Federal para la Protección contra Riesgos Sanitarios | 59797 |
| NL | Z-Index G-Standaard, PRK | 159, 17442, 20389, 21822 |
| NZ | Medicines and Medical Devices Safety Authority | 293, 294, 296, 297, 299 |
| PL | Rejestru Produktów Leczniczych | 100056339, 100056345 |
| SG | Health Sciences Authority | 03841P, 10513P |
| US | FDA, National Drug Code | 0009-0050, 0009-0051, 0009-0065, 0009-0286, 0009-0287 |
| ZA | Health Products Regulatory Authority | S/21.8.2/1, W/21.8.2/462, Z/21.8.2/363 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.